In a significant milestone reflecting renewed financial strength and long-term growth, Morepen Laboratories Ltd. (NSE: MOREPENLAB; BSE: 500288) has proposed a dividend of ?0.20 per share—its first in 23 years. The proposal is subject to shareholder approval at the upcoming Annual General Meeting and marks a historic moment in the company’s four-decade journey.
The announcement follows an exceptional financial performance in FY25. Gross revenue rose 7.4% year-on-year to ?1,830 crore from ?1,704 crore in FY24. EBITDA increased 21.6% to ?118 crore, while Profit After Tax (PAT) also touched ?118 crore. Earnings Per Share (EPS) climbed 17% to ?2.20.
Sushil Suri, Chairman & Managing Director, commented, “This moment is symbolic—it’s not just about distributing profits but rewarding trust. Declaring a dividend after 23 years reflects our financial resilience, operational excellence, and a long-term vision rooted in sharing and caring. Our shareholders have stood by us, and it’s time to give back.”
Morepen’s Active Pharmaceutical Ingredients (API) segment led the way, contributing ?989 crore, with 72% of that coming from exports to over 80 countries. Meanwhile, the Medical Devices segment posted a strong 12% year-on-year growth, reaching ?496 crore. The company continues to invest in new product development, capacity expansion, and global regulatory approvals, reinforcing its position as an emerging global pharmaceutical leader.